In the previous study, the expression of FBL can be regulated by p53 in multiple tumors and was considered as an ideal target to inhibit the ribosome biogenesis process in cancer therapy (Marcel et al., 2013; El Hassouni et al., 2019). The gene discussed is FBL; the disease is cancer.